RGNX

RGNX R&D Expenses

$229.14MTTM · USD

Period ending:

RGNX FY R&D ExpensesUSD
RGNX FY R&D Expenses2013-12-31: $5.05M2014-12-31: $4.96M2015-12-31: $17.28M2016-12-31: $45.48M2017-12-31: $57.22M2018-12-31: $83.87M2019-12-31: $124.19M2020-12-31: $166.29M2021-12-31: $181.44M2022-12-31: $242.45M2023-12-31: $232.27M2024-12-31: $208.52M2025-12-31: $228.30M$242.45M$0.00
2013-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

RGNX r&d expenses history

Research and development spending. The available annual fiscal periods series contains 13 observations from Dec 31, 2013 to Dec 31, 2025.

Regenxbio Inc R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
228,299,000
208,522,000
232,266,000
242,453,000
181,437,000
166,294,000
124,185,000
83,873,000
57,224,000
45,482,000
17,279,000
4,961,000
5,051,000

Compare r&d expenses

All RGNX financial metrics · RGNX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.